SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

RF9

Item No. 31412

CAS Registry No.: 876310-60-0
Formal Name: N^2-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)-L-arginyl-L-phenylalaninamide
MF: $C_{26}H_{38}N_6O_3$
FW: 482.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

RF9 is supplied as a solid. A stock solution may be made by dissolving the RF9 in the solvent of choice, which should be purged with an inert gas. RF9 is soluble in organic solvents such as DMSO. It is also soluble in water. The solubility of RF9 in DMSO and water is approximately 5 and 20 mg/ml, respectively. We do not recommend storing the aqueous solution for more than one day.

Description

RF9 is a neuropeptide FF (NPFF) receptor antagonist.[1] It binds to human NPFF1 and NPFF2 receptors with K_i values of 58 and 75 nM, respectively. It is selective for NPFF1 and NPFF2 receptors over neuropeptide Y (NPY) receptor Y_1, GPR10, GPR54, GPR103, ORL-1, and μ-, δ-, and κ-opioid receptors at 10 μM. RF9 (7.5 μM) inhibits NPFF-induced [^{35}S]GTPγS binding to the NPFF2 receptor. It reverses NPVF-induced inhibition of forskolin-stimulated cAMP accumulation in CHO cells expressing the human NPFF1 receptor (EC_{50} = 4.7 μM). Intracerebroventricular administration of RF9 (10 μg) inhibits NPFF-induced increases in mean arterial pressure and heart rate in rats. It prevents heroin-induced delayed hyperalgesia and associated tolerance in rats when administered subcutaneously at a dose of 0.1 mg/kg.

Reference

1. Simonin, F., Schmitt, M., Laulin, J.-P., *et al.* RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. *Proc. Natl. Acad. Sci. USA* **103(2)**, 466-471 (2006).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM